On the public citation graph
Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line
0 signed · 87 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/978-1-60761-416-6_21openalex-snapshot
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
inferredcites →https://doi.org/10.1007/978-981-10-6020-5_4openalex-snapshot
Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
inferredcites →https://doi.org/10.1016/0092-8674(94)90518-5openalex-snapshot
Apoptosis in cancer therapy: Crossing the threshold
inferredcites →https://doi.org/10.1016/j.bbcan.2023.188866openalex-snapshot
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
inferredcites →https://doi.org/10.1016/j.biopha.2016.06.051openalex-snapshot
Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin
inferredcites →https://doi.org/10.1016/j.biopha.2020.110048openalex-snapshot
Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways
inferredcites →https://doi.org/10.1016/j.breast.2022.08.010openalex-snapshot
Current and future burden of breast cancer: Global statistics for 2020 and 2040
inferredcites →https://doi.org/10.1016/j.drudis.2020.04.003openalex-snapshot
The combination of disulfiram and copper for cancer treatment
inferredcites →https://doi.org/10.1016/j.ijpharm.2020.119191openalex-snapshot
Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells
inferredcites →https://doi.org/10.1016/j.redox.2021.102122openalex-snapshot
Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis
inferredcites →https://doi.org/10.1016/j.tips.2019.08.002openalex-snapshot
Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics
inferredcites →https://doi.org/10.1038/bjc.2013.534openalex-snapshot
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells
inferredcites →https://doi.org/10.1038/emm.2017.38openalex-snapshot
Methylation and demethylation of DNA and histones in chromatin: the most complicated epigenetic marker
inferredcites →https://doi.org/10.1038/nature02625openalex-snapshot
Epigenetics in human disease and prospects for epigenetic therapy
inferredcites →https://doi.org/10.1038/nm.2919openalex-snapshot
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
inferredcites →https://doi.org/10.1038/s12276-020-0384-2openalex-snapshot
ROS in cancer therapy: the bright side of the moon
inferredcites →https://doi.org/10.1038/s41392-023-01332-8openalex-snapshot
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
inferredcites →https://doi.org/10.1038/s41598-020-60409-4openalex-snapshot
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
inferredcites →https://doi.org/10.1038/srep22847openalex-snapshot
Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption
inferredcites →https://doi.org/10.1039/d0bm00062kopenalex-snapshot
Disulfiram-gold-nanorod integrate for effective tumor targeting and photothermal-chemical synergistic therapy
inferredcites →https://doi.org/10.1042/bcj20180440openalex-snapshot
lncRedibly versatile: biochemical and biological functions of long noncoding RNAs
inferredcites →https://doi.org/10.1093/annonc/mdm204openalex-snapshot
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
inferredcites →https://doi.org/10.1093/annonc/mdn728openalex-snapshot
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk
inferredcites →https://doi.org/10.1093/nar/gkac1000openalex-snapshot
The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest
inferredcites →https://doi.org/10.1101/cshperspect.a019505openalex-snapshot
Epigenetic Determinants of Cancer
inferredcites →https://doi.org/10.1111/ajco.13443openalex-snapshot
A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma
inferredcites →https://doi.org/10.1155/2013/137414openalex-snapshot
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
inferredcites →https://doi.org/10.1158/1535-7163.mct-06-0663openalex-snapshot
Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets
inferredcites →https://doi.org/10.1186/1471-2121-12-2openalex-snapshot
Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication
inferredcites →https://doi.org/10.1186/1479-5876-4-10openalex-snapshot
Hydralazine target: From blood vessels to the epigenome
inferredcites →https://doi.org/10.1186/1479-5876-4-32openalex-snapshot
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
inferredcites →https://doi.org/10.1186/s13046-019-1160-9openalex-snapshot
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
inferredcites →https://doi.org/10.1186/s13148-019-0776-0openalex-snapshot
The timeline of epigenetic drug discovery: from reality to dreams
inferredcites →https://doi.org/10.1186/s13578-019-0312-0openalex-snapshot
Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
inferredcites →https://doi.org/10.1371/journal.pone.0000098openalex-snapshot
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0087366openalex-snapshot
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
inferredcites →https://doi.org/10.1371/journal.pone.0265497openalex-snapshot
Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension
inferredcites →https://doi.org/10.1513/pats.200504-037sropenalex-snapshot
Pharmacologic Principles for Combination Therapy
inferredcites →https://doi.org/10.18632/oncotarget.16723openalex-snapshot
Combination therapy in combating cancer
inferredcites →https://doi.org/10.18632/oncotarget.5723openalex-snapshot
Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway
inferredcites →https://doi.org/10.18632/oncotarget.7871openalex-snapshot
The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells
inferredcites →https://doi.org/10.20517/cdr.2018.11openalex-snapshot
Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
inferredcites →https://doi.org/10.20517/cdr.2019.10openalex-snapshot
Drug resistance and combating drug resistance in cancer
inferredcites →https://doi.org/10.20517/cdr.2020.06openalex-snapshot
Epigenetic basis of cancer drug resistance
inferredcites →https://doi.org/10.21037/atm.2016.11.82openalex-snapshot
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets
inferredcites →https://doi.org/10.2174/1871520615666160504095040openalex-snapshot
Disulfiram';s Anticancer Activity: Evidence and Mechanisms
inferredcites →https://doi.org/10.3322/caac.21660openalex-snapshot
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
inferredcites →https://doi.org/10.3389/fcell.2021.645518openalex-snapshot
Sodium Valproate-Induced Chromatin Remodeling
inferredcites →https://doi.org/10.3389/fonc.2020.00265openalex-snapshot
Perplexing Role of P-Glycoprotein in Tumor Microenvironment
inferredcites →https://doi.org/10.3389/fonc.2020.605386openalex-snapshot
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
inferredcites →https://doi.org/10.3389/fonc.2022.891652openalex-snapshot
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
inferredcites →https://doi.org/10.3389/fphar.2013.00089openalex-snapshot
Mechanisms regulating resistance to inhibitors of topoisomerase II
inferredcites →https://doi.org/10.3389/fphar.2022.1072651openalex-snapshot
Recent progress in DNA methyltransferase inhibitors as anticancer agents
inferredcites →https://doi.org/10.3390/cancers10120483openalex-snapshot
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
inferredcites →https://doi.org/10.3390/cancers12010162openalex-snapshot
Improvement in the Anti-Tumor Efficacy of Doxorubicin Nanosponges in In Vitro and in Mice Bearing Breast Tumor Models
inferredcites →https://doi.org/10.3390/ijms20153696openalex-snapshot
Downregulation of STAT3, β-Catenin, and Notch-1 by Single and Combinations of siRNA Treatment Enhance Chemosensitivity of Wild Type and Doxorubicin Resistant MCF7 Breast Cancer Cells to Doxorubicin
inferredcites →https://doi.org/10.3390/ijms20194783openalex-snapshot
New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer
inferredcites →https://doi.org/10.3390/ijms21093233openalex-snapshot
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
inferredcites →https://doi.org/10.3390/ijms22095047openalex-snapshot
Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review
inferredcites →https://doi.org/10.3390/md17090536openalex-snapshot
Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells
inferredcites →https://doi.org/10.3892/or.2017.5972openalex-snapshot
DNA methylation and histone modifications as epigenetic regulation in prostate cancer
inferredcites →https://doi.org/10.4161/cc.26063openalex-snapshot
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: Interaction with IQ motif-containing factors
inferredcites →https://doi.org/10.5772/48591openalex-snapshot
Aldehyde Dehydrogenase: Cancer and Stem Cells
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.3897/pharmacia.73.e159454zenodo-depositor-declared
Ononin synergistically enhances the cytotoxic effect of doxorubicin in MDA-MB-231 triple-negative breast cancer cell line
inferred← citeshttps://doi.org/10.1002/adfm.202512905openalex-snapshot
Precision Cuproptosis Activation via HER2‐Targeted Bimetallic MOF Nanoreactors Breaks Metabolic Adaptation in Aggressive Breast Cancers
inferred← citeshttps://doi.org/10.1002/cbdv.202401561openalex-snapshot
Hydralazine and Hydrazine Derivatives: Properties, Applications, and Repositioning Potential
inferred← citeshttps://doi.org/10.1007/s12032-024-02567-3openalex-snapshot
Metal–organic frameworks as nanoplatforms for combination therapy in cancer treatment
inferred← citeshttps://doi.org/10.1007/s13346-024-01648-0openalex-snapshot
A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer
inferred← citeshttps://doi.org/10.1007/s40262-024-01391-2openalex-snapshot
Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges
inferred← citeshttps://doi.org/10.1016/j.biopha.2026.119615openalex-snapshot
Emerging mechanistic insights into cuproptosis in cancer: Metabolic rewiring and therapeutic targeting
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118364openalex-snapshot
The 2-aminopyrimidine ring as a new scaffold for potent MRP1 inhibitors
inferred← citeshttps://doi.org/10.1021/acsami.5c10365openalex-snapshot
A Redox Cleavable and Targeting Nanoassembly Based on CPT/DOXY Conjugates for Synergistically Enhanced Chemo/Photodynamic/Photothermal Combined Tumor Therapy
inferred← citeshttps://doi.org/10.1080/15287394.2024.2448663openalex-snapshot
Buthionine sulfoximine acts synergistically with doxorubicin as a sensitizer molecule on different tumor cell lines
inferred← citeshttps://doi.org/10.1080/17435889.2025.2459059openalex-snapshot
Formation and evaluation of doxorubicin and cromoglycate metal–organic framework for anti-cancer activity
inferred← citeshttps://doi.org/10.1080/21691401.2025.2507372openalex-snapshot
Investigating the anticancer and synergistic effects of the combination of green synthesized silver nanoparticles and papaverine on breast cancer cell lines: focusing on the apoptosis pathway and microRNA regulation
inferred← citeshttps://doi.org/10.1186/s12935-024-03572-2openalex-snapshot
Cuproptosis: a promising new target for breast cancer therapy
inferred← citeshttps://doi.org/10.1186/s13045-024-01589-8openalex-snapshot
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives
inferred← citeshttps://doi.org/10.1186/s13045-026-01831-5openalex-snapshot
Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities
inferred← citeshttps://doi.org/10.22159/ijap.2025v17i3.53441openalex-snapshot
HPLC METHOD DEVELOPMENT AND VALIDATION FOR METFORMIN AND PHENYL BUTYRIC ACID AND IN VITRO EVALUATION OF THEIR PEGYLATED LIPOSOMAL FORMULATION AGAINST COLORECTAL CANCER
inferred← citeshttps://doi.org/10.3389/fphar.2024.1493188openalex-snapshot
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application
inferred← citeshttps://doi.org/10.3390/biom16040562openalex-snapshot
Impact of N-Acetylation on DNA Damage and Oxidative Stress Responses in Mammalian Cells and Human Hepatocytes Treated with Hydralazine
inferred← citeshttps://doi.org/10.3390/cancers16081463openalex-snapshot
Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing
inferred← citeshttps://doi.org/10.3390/molecules30071549openalex-snapshot
Remote Co-Loading of Doxorubicin and Hydralazine into PEGylated Liposomes: In Vitro Anti-Proliferative Effect Against Breast Cancer
inferred← citeshttps://doi.org/10.3390/molecules30244747openalex-snapshot
Novel Trinorditerpene from Dysoxylum parasiticum (Osbeck) Kosterm: Leaf Extract with Cytotoxic, Antioxidant and α-Glucosidase Inhibitory Activities
inferred← citeshttps://doi.org/10.48084/etasr.10900openalex-snapshot
Enhancing Breast Cancer Classification based on BPSO Feature Selection and Machine Learning Techniques
inferred← citeshttps://doi.org/10.54133/ajms.v10i2.2860openalex-snapshot
Adapting Hydralazine as a Reliable Low-Toxicity Alternative to Cobalt Chloride for Hypoxia Modeling in Breast Cancer Cells
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.